Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 2/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | KCNN4 | O15554 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6850 | 0.81 | MAPK1 (0.50) | MAPK1ALDH1A1TAAR1ALOX15ESR1 | |
| SCHEMBL9669699 | 0.75 | MAPK1 (0.50) | MAPK1ALDH1A1TAAR1ALOX15ESR1 | |
| SCHEMBL18127935 | 0.75 | MAPK1 (0.50) | MAPK1ALDH1A1TAAR1ALOX15ESR1 | |
| SCHEMBL207978 | 0.75 | MAPK1 (0.50) | MAPK1ALDH1A1TAAR1ALOX15ESR1 | |
| SCHEMBL240161 | 0.75 | MAPK1 (0.50) | MAPK1ALDH1A1TAAR1ALOX15ESR1 | |
| SCHEMBL96177 | 0.73 | MAPK1 (0.55) | MAPK1ALDH1A1TAAR1ALOX15ESR1 | |
| Tert-Butylbenzene SCHEMBL18889 | 0.73 | MAPK1 (0.55) | MAPK1ALDH1A1TAAR1ALOX15ESR1 | |
| Tert-Butylbenzene SCHEMBL22264599 | 0.73 | MAPK1 (0.55) | MAPK1ALDH1A1TAAR1ALOX15ESR1 | |
| Tert-Butylbenzene SCHEMBL22264597 | 0.73 | MAPK1 (0.55) | MAPK1ALDH1A1TAAR1ALOX15ESR1 | |
| SCHEMBL35881 | 0.73 | ESR1 (0.70) | MAPK1ALDH1A1TAAR1ALOX15ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114773347-A | Benzimidazole compound based on ortho-substitution and application thereof | 宁波卢米蓝新材料有限公司 | 2022-07-22 | — | — | CN | claimed |
| CN-114736208-A | Benzimidazole compound based on multi-donor substitution and application thereof | 宁波卢米蓝新材料有限公司 | 2022-07-12 | — | — | CN | claimed |
| CN-114507219-A | Organic compound based on naphthalimide and application thereof | 宁波卢米蓝新材料有限公司 | 2022-05-17 | — | — | CN | claimed |
| CN-108129429-B | Naphthalene benzofuran derivative and preparation method thereof | 张家港九力新材料科技有限公司 | 2021-07-20 | — | — | CN | claimed |
| EP-1778712-B1 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | Univ Virginia Patent Found (US) | 2013-01-30 | — | — | EP | claimed |
| US-8188063-B2 | A2A receptor agonists for the central nervous system; antiinflammatory agents; 2,7-disubstituted-5-amino-pyrazolo[4,3-e]-[1,2,4]-triazolo[1,5-c]pyrimidines, mefloquine, 8-(3-chlorostyryl)caffeine, 3,7,8-trisubstituted-1-propargyl-xanthines; 2,5-disubstituted-7-amino-[1,2,4]triazolo[1,5-a][1,3,5]triazines | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-29 | — | — | US | claimed |
| US-8178509-B2 | Method to treat sickle cell disease | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-15 | — | — | US | claimed |
| US-8158604-B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-04-17 | — | — | US | claimed |
| US-20100152127-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-06-17 | — | — | US | claimed |
| US-7737127-B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-06-15 | — | — | US | claimed |
| WO-2006015357-A2 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2006-02-09 | — | — | WO | claimed |
| US-20050282831-A1 | Selective antagonists of A2A adenosine receptors | ADENOSINE THERAPEUTICS, LLC | 2005-12-22 | — | — | US | claimed |
| US-20050261236-A1 | Agonists of A2A adenosine receptors for treatment of diabetic nephropathy | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-11-24 | — | — | US | claimed |
| WO-2005097140-A2 | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC (US) | 2005-10-20 | — | — | WO | claimed |
| US-20050182018-A1 | Method to reduce inflammatory response in transplanted tissue | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-08-18 | — | — | US | claimed |
| EP-1496911-A1 | USE OF A2A ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2005-01-19 | — | — | EP | claimed |
| EP-1434782-A2 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | University of Virginia Patent Foundation (US) | 2004-07-07 | — | — | EP | claimed |
| WO-2003086408-A1 | USE OF A2A ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2003-10-23 | — | — | WO | claimed |
| US-20030186926-A1 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-02 | — | — | US | claimed |
| WO-2003029264-A2 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2003-04-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282831-A1 | Selective antagonists of A2A adenosine receptors | ADORA2A, ADORA2B, ADORA3 | MAPK1 4096/4885ALDH1A1 1444/4885TAAR1 92/4885 |
| US-20050261236-A1 | Agonists of A2A adenosine receptors for treatment of diabetic nephropathy | ADORA2A, ADORA3, PDE4A | MAPK1 3567/4885ALDH1A1 605/4885TAAR1 135/4885 |
| US-20050182018-A1 | Method to reduce inflammatory response in transplanted tissue | ADORA2A, PDE4A, PDE4B | MAPK1 3726/4885ALDH1A1 644/4885TAAR1 323/4885 |
| US-20100152127-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | ADORA2A, ADORA3, ADORA1 | MAPK1 3494/4885ALDH1A1 635/4885TAAR1 128/4885 |
| US-20030186926-A1 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | ADORA2A, ADORA1, ADORA3 | MAPK1 3321/4885ALDH1A1 500/4885TAAR1 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.